Plain-English translation of NCT07172516 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bipolar Disorder research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help treat depression in people with bipolar I or II disorder. About 400 people will participate in this trial, with some receiving the new medication and others receiving a placebo (an inactive pill). The study will measure whether this treatment reduces depressive symptoms and is safe to use.
Depression in bipolar disorder can be difficult to treat, and current options don't work well enough for everyone. This trial is exploring whether this medication could offer a new, more effective treatment option for people struggling with bipolar depression.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication or a placebo pill. Neither you nor the research team will know which you're receiving—this is called a 'blinded' study, designed to keep results fair and objective. You will attend multiple visits at a research center where staff will monitor your mood, check your physical health, and ask about any side effects you experience. The study takes place across multiple centers, so you'll work with a local research team near you.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
United States